Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2014

View Archived Issues

University of Bath patents novel deuterated estradiol derivatives

Novel glucan synthase inhibitors disclosed by Evolva

FDA removes partial clinical hold on vantictumab trials

Acusphere withdraws European MAA for Imagify

EWAS in Alzheimer's patients reveals involvement of ANK1 gene

Researchers develop biomimetic microfluidic model using primary human cells

Preclinical evaluation of novel GPR120 agonist for improved glucose control in obese mice

NIH set to begin phase I safety studies of Ebola virus vaccines

Merck KGaA discloses novel IRAK inhibitors

Nissan Chemical prepares novel JAK inhibitors

Merck KGaA divulges new mGlu4 receptor PAMs

Phase I study of MGCD-516 recruiting patients with solid tumors

Wockhardt's WCK-771 and WCK-2349 receive FDA QIDP status

Darapladib fails to prevent cardiac events in SOLID-TIMI 52 trial

Green Cross begins phase II trial of Hepabig-gene

Clinical investigation of CFZ-533 continues with phase I/II study

Kyowa Hakko Kirin begins Japanese study of KHK-7580 for secondary hyperparathyroidism

Additional NIAID funding supports study of BioCryst's BCX-4430 for Ebola

Senesco closes enrollment in phase Ib/IIa trial of SNS01-T

Telik updates progress of development of 5B1 for gastrointestinal cancers

TGen cleared to open enrollment in glioblastoma trial

FDA approves Vimpat as monotherapy for partial-onset seizures

Vizamyl approved in E.U. for PET imaging of beta-amyloid plaques

European orphan drug designation awarded to AMY-101 for PNH

Four products recently granted orphan drug designation in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...